Jump to content
PathLabTalk

Abdulhameed Al-Attas

Members
  • Posts

    135
  • Joined

  • Last visited

  • Days Won

    1
  • Country

    Saudi Arabia

Abdulhameed Al-Attas last won the day on June 30 2014

Abdulhameed Al-Attas had the most liked content!

About Abdulhameed Al-Attas

  • Birthday 10/10/1962

Profile Information

  • Gender
    Male
  • Interests
    Reading,lecturing and cooking
  • Location
    Jeddah,Saudi Arabia
  • Occupation
    Clinical Laboratory Scientist
  • Real Name
    ABDULHAMEED AL ATTAS

Recent Profile Visitors

1,683 profile views

Abdulhameed Al-Attas's Achievements

  1. Volume-reduced platelet concentrates (PCs) can be a useful option for transfusing a high number of platelets in the smallest possible plasma volume, especially in neonatal and other pediatric patients. In addition to decreasing the risk of circulatory overload, volume-reduced PCs contain less plasma, which may reduce the likelihood of adverse plasma-related transfusion reactions.
  2. Low-incidence antigens are not usually found on screen cell and antibody panels. Antibodies are hard to test for, but it is usually not difficult to find compatible blood. Suspect this antibody if an AHG crossmatch is incompatible and other causes have been ruled out, such as a positive donor DAT or ABO incompatibility. Examples of low-incidence antigens include: Cw, V, Kpa, Jsa. When going through the process of Ruling Out, antibodies like anti-V, anti-Cw, anti-Lua, anti-Kpa, and anti-Jsa usually fall into the "unable to rule out" category.
  3. I have also never seen a case of ABO HDFN in a non group O mom which is severe enough to warrant clinical intervention in 30 years.
  4. Yes, as Terri has mentioned the Medical Director is the one who interpretes the Transfusion Reaction,so untill he/she interpretes NO further Transfusions. And we put a note for that to alert coleuges. The reaction could be from Anti- IgA that requires either IgA deficiency blood or washed RBC's OR FNHTR that may require Leukoreduced or HLA match in case of Platelets.
  5. It depends the reason for transfusion if it's to restore coagulation factors my answer will NO because of compromised coagulation factor activity,namely factor V and VIII.
  6. What about if you get your SBB from Gulf Coast Regional Blood Center just for $ 3,000 per year ( 12 Months ), here is website http://www.giveblood.org/education/sbb-distance-program/ and then go to GW for Master of Transfusion Medicine NOT Lab Management for $ 12,000.
  7. Anorris, I am afraid your report looks like a dilution rather than a titer.
  8. We ONLY irradiate the Cellular Components, FFP and Cryoprecipitate are NOT cellular components.
  9. too weak to titer, I agree with Eagle Eye.
  10. The ABO/Rh confirmatory policy has been developed to prevent transfusion from a misidentified sample. Our guidelines states unless electronic patient identification systems are in place, a second sample should be requested for confirmation of the ABO/Rh group of the first time patient prior to transfusion, where this does NOT impede the delivery of urgent red cells or other components. The ABO/Rh confirmatory is a STAT test and should be handeled accordingly, it must be from a seperate collection phlebotomy and collected at a different time from the initial one. It should NOT be a retained sample from the initial collection and delivered as a second one after Bank Bank calls for a ABO/Rh confirmatory sample. Yes,post 4 months of age, we require a confirmatory sample, as MAGNUM stated. We must always remember that the most important test done in the Blood Bank is ABO grouping.
  11. YES, 24 hours, at Room temperature and without agitation.
  12. I agree with both David and Anna for their respective suggestions of an enzyme pretreated panel in gel and extended phenotype on the pre-transfusion sample. You have done an elution on the patient's post-transfusion red cells, and the resulting eluate tested for antibody specificity. Note that in this case, even though the antibody elutes from the patient's red cells, it is NOT an autoantibody as it actually eluted from the donor's red cells now in the patient's circulation.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.